These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 32344513

  • 21. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
    Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y, Wang X.
    Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E.
    Oncogene; 2012 Nov 01; 31(44):4718-24. PubMed ID: 22266871
    [Abstract] [Full Text] [Related]

  • 23. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C.
    Clin Exp Pharmacol Physiol; 2014 Oct 01; 41(10):817-24. PubMed ID: 25115435
    [Abstract] [Full Text] [Related]

  • 24. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W, Melton DW.
    Oncogene; 2012 May 10; 31(19):2412-22. PubMed ID: 21996734
    [Abstract] [Full Text] [Related]

  • 25. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair.
    Cummings M, Higginbottom K, McGurk CJ, Wong OG, Köberle B, Oliver RT, Masters JR.
    Biochem Pharmacol; 2006 Jul 14; 72(2):166-75. PubMed ID: 16756962
    [Abstract] [Full Text] [Related]

  • 26. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.
    Acta Biomater; 2017 Jan 01; 47():71-80. PubMed ID: 27697601
    [Abstract] [Full Text] [Related]

  • 27. Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.
    Wang W, Zhang L, Liu L, Zheng Y, Zhang Y, Yang S, Shi R, Wang S.
    Oncol Rep; 2017 Apr 01; 37(4):1989-1997. PubMed ID: 28260069
    [Abstract] [Full Text] [Related]

  • 28. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
    Xu X, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, Shi J, Wu J, Kantoff PW, Lippard SJ, Langer R, Walker GC, Farokhzad OC.
    Proc Natl Acad Sci U S A; 2013 Nov 12; 110(46):18638-43. PubMed ID: 24167294
    [Abstract] [Full Text] [Related]

  • 29. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 12; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 30. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F, Barakat KH, Tuszynski JA.
    Int J Mol Sci; 2018 Apr 30; 19(5):. PubMed ID: 29710850
    [Abstract] [Full Text] [Related]

  • 31. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F, Tuszynski JA, Barakat KH.
    J Mol Graph Model; 2016 Apr 30; 65():71-82. PubMed ID: 26939044
    [Abstract] [Full Text] [Related]

  • 32. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
    Wang S, Pan H, Liu D, Mao N, Zuo C, Li L, Xie T, Huang D, Huang Y, Pan Q, Yang L, Wu J.
    Int J Oncol; 2015 Feb 30; 46(2):809-17. PubMed ID: 25434755
    [Abstract] [Full Text] [Related]

  • 33. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S.
    Anticancer Res; 2010 Jul 30; 30(7):2531-8. PubMed ID: 20682979
    [Abstract] [Full Text] [Related]

  • 34. Applications of genomics in NSCLC.
    Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, Altavilla G, Santarpia M, Moran T, Catot S, Etxaniz O.
    Lung Cancer; 2005 Dec 30; 50 Suppl 2():S33-40. PubMed ID: 16557672
    [Abstract] [Full Text] [Related]

  • 35. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA.
    Chem Biol Drug Des; 2020 Apr 30; 95(4):460-471. PubMed ID: 31891209
    [Abstract] [Full Text] [Related]

  • 36. Microfluidic Assembly of siRNA-Loaded Micelleplexes for Tumor Targeting in an Orthotopic Model of Ovarian Cancer.
    Feldmann DP, Jones S, Douglas K, Shields AF, Merkel OM.
    Methods Mol Biol; 2019 Apr 30; 1974():355-369. PubMed ID: 31099014
    [Abstract] [Full Text] [Related]

  • 37. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM, Melton DW.
    Nucleic Acids Res; 2012 Nov 01; 40(20):9990-10004. PubMed ID: 22941649
    [Abstract] [Full Text] [Related]

  • 38. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 01; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
    Tsai MS, Weng SH, Chen HJ, Chiu YF, Huang YC, Tseng SC, Kuo YH, Lin YW.
    Mol Cancer Ther; 2012 Mar 01; 11(3):561-71. PubMed ID: 22053010
    [Abstract] [Full Text] [Related]

  • 40. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW.
    Mol Pharmacol; 2011 Jul 01; 80(1):136-46. PubMed ID: 21493726
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.